-transparent.png){kind=logo}
We evaluated the efficacy, safety and tolerability of a new dopamine D-2 receptor agonist, pramipexole [(S)-2-amino-4,5,6,7-tetrahydro-6-propylamino-benzathiazol-dihydro chloride], as adjunctive therapy in patients with advanced Parkinson's disease (PD). Twenty-four PD patients with motor fluctuations were treated in an 11 week prospective, single-blind parallel-group, placebo-controlled trial. The pramipexole treated group experienced a significant improvement in "off" time functioning as measured by the activities of daily living portion of the United Parkinson's Disease Rating Scale. In addition, the active treatment group was able to reduce total levodopa dose by 30% (p < 0.05). Pramipexole was well tolerated and the side effects reported were typical of other dopamine agonists. We conclude that pramipexole has antiparkinsonian effects which make it potentially useful in the treatment of motor fluctuations in PD.
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
May 2000,
European journal of neurology,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
October 2006,
Journal of the neurological sciences,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
September 1997,
Neurology,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
February 1999,
Journal of the neurological sciences,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
September 2001,
Expert review of neurotherapeutics,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
January 1999,
Clinical neuropharmacology,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
May 1987,
Neurology,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
December 2011,
Hiroshima journal of medical sciences,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
January 1998,
Clinical neuropharmacology,
E S Molho, and
S A Factor, and
W J Weiner, and
J R Sanchez-Ramos, and
C Singer, and
L Shulman, and
D Brown, and
C Sheldon
May 2009,
Journal of movement disorders,
